BioSpace News Archive

Rapid Micro Biosystems, Inc. announced its financial results for the third quarter ended September 30, 2022.

BioXcel Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2022 and provided an update on key strategic initiatives.

Pluri Inc., a leading biotechnology company, won Cell Innovation award in the Cell Biology category of the second annual BioTech Breakthrough Awards.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended September 30, 2022, and provided operational updates.

GH Research PLC reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.

Bio-Techne Corporation announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stephens Annual Investment Conference on Thursday, November 17, 2022, at 10:00 a.m. CST.

UCB announced the first presentation of long-term, 52-week data from three Phase 3 studies evaluating the efficacy and safety of bimekizumab in adults with active psoriatic arthritis who were biologic-naïve, in adults with active non-radiographic axial spondyloarthritis, and in adults with active ankylosing spondylitis.

BioLineRx Ltd. announced that the U.S. Food and Drug Administration has accepted for review and filed the Company’s New Drug Application for APHEXDA® in stem cell mobilization for autologous transplantation in multiple myeloma patients.

Element Biosciences, Inc. announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, giving the Element AVITI System the power of both short- and long-read sequencing on the same instrument.

ESSA Pharma Inc. today announced that the Company will be participating in two upcoming investor conferences.